TABLE 2.

The effect of one by one trial in the association between liraglutide use and cardiometabolic profiles using sensitivity analysis.

Variable	Pre-sensitivity analysis			Upper and lower of effect size	Post-sensitivity analysis
	No. of studies included	Pooled WMD	95% CI		Pooled WMD	95% CI	Excluded studies
HbA1C	6	−0.36	−0.47, −0.26	Upper	−0.34	−0.45, −0.24	Chen et al. (2015)
				Lower	−0.38	−0.50, −0.27	Chen et al. (2016)
BMI	5	−0.61	−1.21, −0.01	Upper	−0.41	−1.14, 0.30	Anholm et al. (2017)
				Lower	−0.99	−1.34, −0.64	Chen et al. (2016)
WC	3	−2.41	−3.47, −1.36	Upper	−2.26	−3.50, −1.01	Kumarathurai et al. (2017)
				Lower	−2.50	−3.79, −1.22	Kumarathurai et al. (2016)
SBP	5	−2.36	−5.45, 0.72	Upper	−0.49	−5.00, 4.02	Chen et al. (2015)
				Lower	−3.77	−7.34, −0.20	Kumarathurai et al. (2017)
DBP	5	1.51	−1.32, 4.35	Upper	2.47	−1.15, 6.10	Chen et al. (2015)
				Lower	0.19	−3.26, 3.65	Kumarathurai et al. (2017)
Heart rate	4	1.83	−2.14, 5.80	Upper	2.81	−2.74, 8.37	Chen et al. (2016)
				Lower	−0.23	−2.82, 2.34	Kumarathurai et al. (2017)
LDL-cholesterol	3	−3.56	−12.68, 5.55	Upper	−3.26	−16.16, 9.63	Anholm et al. (2019)
				Lower	−3.85	−15.44, 7.73	Kumarathurai et al. (2016)

Abbreviations: HbA1c, hemoglobin A1c; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; TG, triglycerides; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein-cholesterol.